NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS
Trident Brands Incorporated (f/k/a Sandfield Ventures Corp.) (“we”, “our”, “the Company”) was incorporated under the
laws of the State of Nevada on November 5, 2007. The Company was formed to engage in the acquisition, exploration and development of natural resource properties.
The Company is now focused on the development of high growth branded and private label consumer products and
ingredients within the nutritional supplement, life sciences and food and beverage categories. The Company is in its early growth stage and has transitioned out of its shell status with the Super-8 filing at the end of August, 2014.
Activities to date have focused on capital formation, organizational development and execution of its branded and private label consumer products and ingredients business plan.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of
Accounting
The Company’s financial statements are prepared using the accrual method of accounting. The Company has elected a
November 30, year-end.
Use of Estimates
and Assumptions
The preparation of financial statements in conformity with generally accepted accounting principles
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. In accordance with ASC
No. 250 all adjustments are normal and recurring.
Principal of
Consolidation
The Company consolidated financial statements as of November 30, 2018 include the accounts of Trident Brands
Incorporated and its subsidiaries: Trident Brands Canada Ltd, Sports Nutrition Products Inc., Brain Armor Inc., Trident Sports Nutrition Inc. and Trident Brands International Ltd.
Earnings (Loss)
Per Share
The Company follows the guidance in ASC No. 260, “Earnings Per Share”, which specifies the computation, presentation
and disclosure requirements for earnings (loss) per share for entities with publicly held common stock.
Basic net earnings (loss) per share amounts are computed by dividing the net earnings (loss) by the weighted average
number of common shares outstanding. Due to net losses during the years ended November 30, 2018 and 2017, diluted earnings (loss) per share are the same as the basic earnings (loss) per share since inclusion of common stock equivalents would
have been anti-dilutive.
Cash Equivalents
The Company considers all highly liquid investments purchased with an original maturity of three months or less to be
cash equivalents.
Accounts
Receivable and Allowance for Doubtful Accounts
Accounts receivable are recorded at their original invoice amounts. We regularly review collectability and establish
an allowance for uncollectible amounts as necessary.
As of November 30, 2018 and 2017, the Company’s accounts receivable was netted against an allowance of $32,383
and $29,852 respectively.
Inventory
Inventories are stated at the lower of cost or net realizable value. Cost is principally determined using the
first-in, first-out (FIFO) method. We regularly review inventory for obsolete and slow moving inventory and write it off as necessary.
Cost Method
Investment
Our cost method investment consists of an investment in a private company in which we do not have the ability to
exercise significant influence over its operating and financial activities. The investment is tested for impairment, at least annually, and more frequently upon the occurrences of certain events.
The Company recognized an impairment on
its cost method investment of $440,542 during the year ended November 30, 2018.
Long-Lived Assets
We review our long-lived assets, including intangible assets subject to amortization, for recoverability whenever
events or changes in circumstances indicate that the carrying amount of such long-lived asset or group of long-lived assets (collectively referred to as "the asset") may not be recoverable. Such circumstances include, but are not limited to:
·
|
a significant decrease in the market price of the asset;
|
·
|
a significant change in the extent or manner in which the asset is being used;
|
·
|
a significant change in the business climate that could affect the value of the asset;
|
·
|
a current period loss combined with projection of continuing loss associated with use of the asset; and
|
·
|
a current expectation that, more likely than not, the asset will be sold or otherwise disposed of before
the end of its previously estimated useful life.
|
We continually evaluate whether such events and circumstances have occurred. When such events or circumstances exist,
the recoverability of the asset's carrying value shall be determined by estimating the undiscounted future cash flows (cash inflows less associated cash outflows) that are directly associated with and that are expected to arise as a direct
result of the use and eventual disposition of the asset.
Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are
amortized on a straight-line basis over their economic or legal life, whichever is shorter The Company currently does not have any amortizable intangible assets. The Company’s indefinite-lived intangible assets consist of trademarks.
The Company reviews its Indefinite-lived intangible assets for impairment annually or whenever events or changes in
circumstances indicate that the carrying amount of the assets may not be fully recoverable. Impairment losses are recognized only if the carrying amount exceeds its fair value.
Beneficial
Conversion Features
The intrinsic value of a beneficial conversion feature inherent to a convertible note payable, which is not
bifurcated and accounted for separately from the convertible note payable and may not be settled in cash upon conversion, is treated as a discount to the convertible note payable. This discount is amortized over the period from the date of
issuance to the date the note is due using the effective interest method. If the note payable is retired prior to the end of its contractual term,the unamortized discount is expensed in the period of retirement to interest expense. In
general, the beneficial conversion feature is measured by comparing the effective conversion price, after considering the relative fair value of detachable instruments included in the financing transaction, if any, to the fair value of the
common shares at the commitment date to be received upon conversion.
Fair Value of
Financial Instruments
The Company measures its financial assets and liabilities in accordance with the requirements of FASB ASC 820, “Fair
Value Measurements and Disclosures”. ASC 820 clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
Level 1– Quoted prices are available in active markets for identical assets or liabilities as of the reporting date.
Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as
exchange-traded derivatives, marketable securities and listed equities.
Level 2 - Pricing inputs are other than quoted prices in active markets included in level 1, which are either
directly or indirectly observable as of the reported date and includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various
assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market andcontractual prices for the underlying instruments, as well as other relevant economic measures.
Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument,
can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest
rate swaps, options and collars.
Level 3–Pricing inputs include significant inputs that are generally less observable fromobjective sources. These
inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.
The carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term
nature of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, accounts payable and note payable. The fair value of the Company’s long-term debt is estimated based on current rates that would be
available for debt of similar terms which is not significantly different from its stated value. As of November 30, 2018 and 2017, the Company did not have any financial assets or liabilities measured and recorded at fair value on the Company’s
consolidated balance sheets on a recurring basis, except for a derivative liability, related to the embedded conversion option on the 2018 convertible note, with a fair value as of November 30, 2018 of $892,000. The derivative liability was
fair valued using Level 3 inputs.
Derivative
Financial Instruments
Fair value accounting requires
bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments and measurement of their fair value for accounting purposes. In assessing the convertible debt instruments, management
determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt under ASC
470, the Company will continue its evaluation process of these instruments as derivative financial instruments under ASC 815. The Company applies the guidance in ASC 815-40-35-12 to determine the order in which each convertible instrument
would be evaluated for derivative classification. The Company’s sequencing policy is to evaluate for reclassification contracts with the earliest inception date first.
Revenue
The Company markets a range of branded and private label consumer products in the active nutrition and dietary
supplement categories including Brain Armor® and P2N Peak Performance Nutrition®.
Two customers accounted for 90.5% and 5.2% of total revenue, compared to 94.3% and 3.7% in the prior year. Two
customers accounted for 59.7% and 17.4% of total accounts receivable, compared to 82.3% and 16.4% in the prior year.
The Company records revenue when all of the following criteria are met: a) persuasive evidence of an arrangement with
the customer exists, b) the price to the customer is fixed and determinable, c) product is shipped or delivery is complete (depending on the terms) and d) collection probability is reasonably assured.
We record a reduction to gross sales based on estimated customer returns and allowances.
Cost of Sales
Cost of sales includes the direct purchase cost of the product based on the FIFO method.
The Company purchased 97% of its products from one vendor for the year ended November 30, 2018 and one vendor provided 99% of
the Company's products for the year ended November 30, 2017.
Employee
Stock-Based Compensation
The Company accounts for employee stock-based compensation in accordance with ASC-718, “Compensation-Stock
Compensation”. ASC-718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments, including stock options, based on the grant-date fair value of the award and to recognize it as
compensation expense over the period the employee is required to provide service in exchange for the award, usually the vesting period.
Non-Employee
Stock-Based Compensation:
The Company accounts for non-employee stock-based compensation in accordance with the provision of ASC 505-50,
“Equity Based Payments to Non-Employees” (“ASC 505-50”), which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment as
the underlying equity instruments vest.
Income Taxes
Income taxes are provided in accordance with ASC No. 740, Accounting for Income Taxes. A deferred tax asset or
liability is recorded for all temporary differences between financial and tax reporting and net operating loss carryforwards. Deferred tax expense (benefit) results from the net change during the year of deferred tax assets and liabilities.
Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than
not that some portion of all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company includes interest and
penalties arising from the underpayment of income taxes in the statements of operation in the provision for income taxes. As of November 30, 2018 and 2017, the Company had no accrued interest or penalties related to uncertain tax positions.
Related Parties
A party is considered to be related to the Company if the party directly or indirectly or through one or more
intermediaries, controls, is controlled by, or is under common control with the Company.
Related parties also include principal owners of the Company, its management, members of the immediate families of
principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the
transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties or if it has an ownership interest in one of the
transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests is also a related party.
Recent Accounting
Pronouncements
The Company has evaluated the following recent accounting pronouncements through the date the financial statements
were issued and filed with the Securities and Exchange Commission and believe that none of them will have a material effect on the Company’s financial statements:
In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts from Customers (Topic 606): Narrow-Scope
Improvements and Practical Expedients. The amendments in this update affect the guidance in ASU 2014-09. The core principle of the guidance in Topic 606 is that an entity should recognize revenue to depict the transfer of promised goods or
services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in ASU 2016-12 do not change the core principle of the guidance in Topic
606, but instead affect only the narrow aspects noted in Topic 606. Topic 606 became effective for the Company on December 1, 2018. Management evaluated Topic 606
and
t
he
modified retrospective
adoption of ASU 2016-12
did not have
any material impact on the Company’s consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718), Scope of Modification
Accounting. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The amendments in this Update are
effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for
reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance.
In July 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). The amendments in Part I of this Update change the classification analysis of certain equity-linked
financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity
classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial
instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments
require entities that present earnings per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common
shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with
Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the
Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years,
beginning after December 15, 2018. For all other entities, the amendments in Part I of this Update are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020.
Early adoption is permitted for all entities, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes
that interim period.
NOTE 3. LIQUIDITY
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a
going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business within one year after the date the consolidated financial statements are issued. In accordance with Financial
Accounting Standards Board, or the FASB, Accounting Standards Update No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40), our management evaluates whether there are conditions or events, considered in
aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.
As of November 30, 2018, the Company had $3,133,303 in cash. However, the Company has generated losses and has a
n accumulated
deficit as of November 30, 2018. The Company completed additional long term financing with the non-US institutional investor, receiving proceeds
of $3,400,780 through the issuance of secured convertible promissory notes. The investor has agreed to make additional investments of $2,804,187 and $3,795,033 ($10,000,000 in the aggregate). Management believes that substantial doubt of our
ability to meet our obligations for the next twelve months from the date these financial statements are issued has been alleviated due to, but not limited to, i) the approval of new financing available to the Company of up to $10,000,000, ii)
continued growth of product sales from our current customer base and new customers, iii) introduction of higher margin products; and iv) controlling of our expenses. We believe that our present and available financial resources will be
sufficient to meet the Company’s obligations and fund our operations at least through the next twelve months from the date these financial statements are issued.
NOTE 4.
ACQUISITION
OF STREAMPAK /
INVESTMENT IN PACKAGING INNOVATION LAB
On September 12, 2017 we entered into a
Share Purchase Agreement dated September 6, 2017 among our wholly owned subsidiary, Trident Brands International Ltd. (“Trident International”), a Bahamas corporation, StreamPak Ltd. (“StreamPak”), an Anguilla corporation, and the sole
shareholder of StreamPak, pursuant to which, in consideration for the payment of $125,000 in cash and 500,000 of our common shares valued at $360,000 based on our stock price on September 6, 2017, Trident International purchased 100% of the
issued and outstanding common shares of StreamPak
.
As a result of the share purchase StreamPak became a wholly owned subsidiary of Trident International.
The acquisition was not deemed an acquisition of a business but rather an acquisition of a finite-lived intangible asset. The total consideration of $485,000 was recognized as an intangible asset related to intellectual property with an
estimated useful life of 10 years. As of July 31, 2018, $44,458 was amortized of which $32,333 was amortized during the current 9 month period and $12,125 in the prior period. The unamortized amount is $440,542.
On July 31, 2018, our wholly owned subsidiary, Trident International, entered into a Stock Purchase Agreement with
Packaging Lab SAS (“Packaging Lab”), whereby Trident International sold all of the issued and outstanding ordinary shares of StreamPak, a wholly owned subsidiary of Trident International, to Packaging Lab in consideration of 1,000 common
shares representing 10% of fully diluted shares in Packaging Innovation Lab. The investment in Packaging Lab was recorded using the cost method of accounting. The Company elected to measure the nonmonetary transaction based on the recorded
amount of StreamPak using the guidance of ASC No. 845 “Non Monetary Transactions” since it was determined that the transaction lacked commercial substance.
The
investment balance of $440,542 was fully impaired as of November 30, 2018.
NOTE 5. NOTE RECEIVABLE
On September 12, 2017 the Company entered into a note purchase agreement with Fengate Trident LP (“Fengate”) pursuant
to which, in consideration for the issuance of 811,887 of our common shares to Fengate, we purchased outstanding secured convertible promissory notes of Mycell Technologies LLC having an aggregate balance due and payable of $511,141
in principal and $94,526 in interest accrued as at September 12, 2017. The purchased notes, which were originally issued to LPF (MCTECH) Investment Corp. on January 22, 2016, February 5, 2016, and May 19, 2016, bear simple interest on unpaid
principal at the rate of ten percent per annum. The outstanding principal and accrued interest is convertible at the option of the note holder into securities of Mycell. The accrued interest as at November 30, 2018 is $1
05,869
.
The Company reserved
a full allowance of $617,010 as of November 30, 2018.
NOTE 6. INTANGIBLE ASSETS
On December 22, 2017, Trident exercised its option under our Exclusive License Agreement (dated March 1, 2015)
to purchase the Brain Armor® brand from DSM Nutrition Products LLC (“DSM”). Subsequently, the parties have executed applicable trademark assignment and purchase agreements necessary to transfer all global intellectual property rights in the
Brain Armor brand to Trident. In lieu of a $400,000USD cash payment to DSM for the value of the Brain Armor® brand as initially intended, the Company agreed to meet certain conditions, that when satisfied will have an equivalent value of
$400,000USD. The costs incurred to meet these conditions are being charged to intangible assets. As of November 30, 2018, the Company has recorded $393,580 of costs to the asset account. Of this amount $200,000 will be paid over time as the
Company purchases omega-3 oil from DSM pursuant to its exclusive supply agreement. During the 12 months ended November 30, 2018, payments of $49,680 were made to DSM in connection with this liability.
NOTE 7. WARRANTS AND OPTIONS
On December 6, 2017, our Board of Directors authorized the issuance to its members and management stock options to
purchase up to 2,615,000 share of our common stock. 1,307,500 of the options vest upon issuance and are exercisable for up to five years at $0.85 per share, while the remaining 1,307,500 will vest 12 months following issuance and be
exercisable for up to five years at $1.00 per share. The Options were issued pursuant to the Company’s 2013 Stock Option Plan, which was registered with the Securities and Exchange Commission on Form S-8 in January, 2015. The 2013 Stock
Option Plan authorizes Trident to issue incentive and non-qualified stock options to employees and consultants of the Company to purchase a number of shares not to exceed 15% of the Company’s currently issued and outstanding securities.
On December 6, 2017, the Board of
Directors authorized the issuance of 250,000 stock options of Brain Armor to Sanitas, LLC, a consultant and founding shareholder of Brain Armor
.
The
options vest immediately and are exercisable for a period of five (5) years to purchase common shares of Brain Armor at $0.75 per share
.
The total
outstanding Brain Armor stock options as of August 31, 2018 are 250,000. The Company used the Black-Scholes model to value the stock options at $95,814
.
The
assumption used was a discount rate of 1.60%, volatility of 85.51% and term of 2.5 years.
The Company used the Black-Scholes model to value the stock options at $1,107,836. For the 12 months ended November
30, 2018, the Company expensed $1,194,775 as compensation expense compared to $6,964 in the previous comparable period. Following are the assumptions used for the options that vested immediately and 12 months from the date of issuance:
Discount rate 1.60% and 2.10%; Volatility 85.51% and 79.75%; and Term 2.5 and 3.0 years.
The following table represents stock option activity as of and for the years ended November 30, 2018 and 2017:
|
|
Number of
Options
|
|
|
Weighted Average
Exercise Price
|
|
|
Contractual
Life in Years
|
|
|
Intrinsic
Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding - November 30, 2016
|
|
|
2,358,333
|
|
|
$
|
0.96
|
|
|
|
2.51
|
|
|
|
|
Exercisable - November 30, 2016
|
|
|
1,666,667
|
|
|
$
|
1.17
|
|
|
|
2.43
|
|
|
$
|
57,500
|
|
Granted
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised or Vested
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited or Expired
|
|
|
(333,333
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding - November 30, 2017
|
|
|
2,025,000
|
|
|
$
|
0.96
|
|
|
|
1.43
|
|
|
|
|
|
Exercisable - November 30, 2017
|
|
|
2,025,000
|
|
|
$
|
0.96
|
|
|
|
1.43
|
|
|
$
|
84,167
|
|
Granted
|
|
|
2,615,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised or Vested
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited or Expired
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding - November 30, 2018
|
|
|
4,640,000
|
|
|
$
|
1.02
|
|
|
|
2.45
|
|
|
|
|
|
Exercisable - November 30, 2018
|
|
|
3,332,500
|
|
|
$
|
1.03
|
|
|
|
1.84
|
|
|
|
0
|
|
As of November 30, 2018, t
he Company has 225,000
outstanding
warrants. The exercise price of the warrants is $1.35 with a term of 3 years and these vested immediately. The Company uses the Black-Scholes model to value the warrants.
Following are the assumptions used: Discount rate
0
.9%; Volatility 76.25% and 77.30% respectively.
The following table represents warrant activity for the years ended November 30, 2018 and 2017:
|
|
Number of
Warrants
|
|
|
Weighted
Average
Exercise Price
|
|
|
Contractual
Life in Years
|
|
|
Intrinsic
Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding – November 30, 2016
|
|
|
225,000
|
|
|
$
|
1.35
|
|
|
|
2.21
|
|
|
|
-
|
|
Exercisable – November 30, 2016
|
|
|
225,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised or Vested
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancelled or Expired
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding – November 30, 2017
|
|
|
225,000
|
|
|
|
1.35
|
|
|
|
1.20
|
|
|
|
-
|
|
Exercisable - November 30, 2017
|
|
|
225,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercised or Vested
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancelled or Expired
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding – November 30, 2018
|
|
|
225,000
|
|
|
$
|
1.35
|
|
|
|
.20
|
|
|
|
-
|
|
NOTE 8. RELATED PARTY TRANSACTIONS
The Company
does not
own any
real or personal property. The Company is paying a director $750 per month rent for use of office space and services.
NOTE 9. CONVERTIBLE
DEBT
On January 29, 2015, the Company entered into a securities purchase agreement with a non-US institutional investor
whereby it agreed to sell an aggregate principal amount of $2,300,000 of senior secured convertible debentures, convertible into shares of the company’s common stock.
The Company received $1,800,000 of the funds from the transaction on February 5, 2015. The balance of $500,000 was
received on May 14, 2015.
These convertible notes were subsequently acquired by Fengate on April 28, 2017.
The convertible debentures are convertible into shares of the Company’s common stock at an initial conversion price
of $0.71 per share, for an aggregate of up to 3,239,437 shares. The debentures originally accrued interest at 6% per annum. On September 26, 2016 the Company entered into an amendment agreement related to these convertible debentures whereby
the applicable interest rate was increased from 6% to 8% and provisions added to allow the investor to transfer, sell or hypothecate the convertible notes subject to applicable securities laws. The maturity date of the notes was also extended
through September 30, 2019. We considered ASC Topic 470-50, Debt Modifications and Extinguishments, and determined that the modification was not deemed substantial.
Due to the note being convertible to common shares of the Company, a beneficial conversion feature analysis was
performed. The intrinsic value of the conversion feature was $647,888 which was recognized as debt discount. As of November 30, 2017, the full amount of the debt discount has been amortized.
On September 26, 2016, the Company entered into a securities purchase agreement with a non-US institutional investor,
pursuant to which, in consideration for proceeds of $4,100,000, the Company issued a secured convertible promissory note in the amount of $4,100,000. Pursuant to the securities purchase agreement, the investor has agreed, from time to time
after January 1, 2017, to make additional investments at the Company’s request of up to $5,900,000 ($10,000,000 in the aggregate) in one or more tranches of not less than one tranche during any 60 day period. The funding of any tranche under
the agreement (other than the first $4,100,000 which has been funded) is subject to the mutual agreement of the parties as to the use of funds.
On May 9, 2017, the Company received the second tranche of funding with proceeds of $4,400,000 and on May 16, 2018
the third tranche of $1,500,000 for a total investment by the investor of $10,000,000.
The Company used the proceeds of the secured convertible note for general working capital purposes including
settlement of accounts payable and repayment of mature loans.
In consideration of each advance made by the investor pursuant to the securities purchase agreement, the Company
issued to the investor a convertible promissory note of equal value, maturing
on September 30, 2019
, and bearing interest at the rate of 8% per annum. Each
note is secured in first priority against the present and after acquired assets of the Company and is convertible in whole or in part at the option of the holder into common shares of the Company at a conversion price of $0.60 per share, for
an aggregate of up to 16,666,667 shares.
These convertible notes were subsequently acquired by Fengate on April 28, 2017.
Due to the notes being convertible to common shares of the Company, a beneficial conversion feature analysis was
performed. The intrinsic value of the conversion feature of the notes amounted to $3,333,33
4
and was recognized as a debt discount. Amortization of the debt
discount charged to interest amounted to $1,263,61
9
and $797,9
09
for the
years ended November 30, 2018 and 2017, respectively. As of November 30, 2018 and 2017 the unamortized discount amounted to $1,190,97
5
and $1,954,59
4
, respectively.
On November 30, 2018 the Company and Fengate entered into a Securities Purchase Amendment Agreement pursuant to which
the Company has agreed to issue to Fengate an additional convertible promissory note (the “2018 Convertible Note”) of up to $10,000,000, subject to certain terms and conditions. Each portion of the principal amount advanced pursuant to the
2018 Convertible Note will bear interest at the rate of twelve percent (12%) per annum and will be payable monthly in arrears to Fengate. Outstanding principal and interest will continue to be secured by the general security agreement dated
September 26, 2016, which forms a part of the Agreement. The holder of the note may also elect from time to time to convert all or a portion of the outstanding principal and interest into common shares of the Company at a 25% discount to the
average closing price of the common shares during the 10 trading days immediately prior to the applicable conversion date. The 2018 Convertible Note will mature on November 30, 2019, provided that Fengate may unilaterally postpone the
maturity date to May 31, 2020.
On November 30, 2018 the Company received the first tranche of funding with proceeds of $3,400,780.
The 2
nd
tranche of $2,804,187 will be made available to the Company once certain funding conditions have been met while the balance of $3,795,033 shall be funded and issued in one or more tranches within 30 days of receipt of written
request from the Company.
The Company intends to use the proceeds of the secured convertible note for general working capital purposes
including, without limitation, product development, inventory, and selling expenses.
The Company analyzed the embedded conversion option
on the convertible notes
for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the conversion option
on the 2018 Convertible Note qualified for derivative accounting
.
The Company used the Black-Scholes model to value the embedded conversion
option at $892,000
.
The assumptions used were a discount rate of 2.8%, volatility of 79.57% and a term of 1.5 years
.
The fair value of the embedded conversion option was recorded as debt discount and will be amortized over the term of the 2018 Convertible Note
.
NOTE 10. COMMITMENTS AND CONTINGENCIES
Everlast License Agreement
On December 23, 2013, the Company entered into a Deed of Assignment Agreement with Everlast
World’s Boxing Headquarters Corporation, International Brand Management Limited, Sports Nutrition Products
Incorporated and Manchester Capital Incorporated wherein Everlast, International Brand, Sports Nutrition and Manchester Capital are parties to a trade mark license and Sports Nutrition, a New York corporation, has assigned its interest in the
trade mark license to the Company. Pursuant to the terms of the assignment agreement, Sports Nutrition Products Incorporated, a wholly owned subsidiary of Trident Brands Incorporated, assigned all of its rights, title, interest and benefit
to the trade mark license to the Company effective December 23, 2013 and the Company assumed all of the obligations of Sports Nutrition Products Incorporated under the license agreement. The Company shall remain responsible to Everlast and
International Brand for all acts and omissions of the subsidiary, Sports Nutrition Products Inc.
The Everlast License Agreement includes a clause stating that Manchester Capital Incorporated will guarantee that the
Licensee shall perform all of its obligations and duties under the Licence Agreement. If the Licensee defaults in the payment when due of any amount it is obliged to pay to Licensor under the Licence Agreement, or arising from its
termination, Manchester Capital is unconditionally responsible to pay that amount to Licensor in the manner prescribed in the Licence Agreement as if it were the Licensee.
The Royalty Calculation, as per the terms of the agreement, are as follows: In 2013, 7% of Net Retail Sales and 7% of
60% of Direct Response Sales Revenue; in 2014, 8% of Net Retail Sales and 8% of 60% of Direct Response Sales Revenue; in 2015, 9% of Net Retail Sales and 9% of 60% of Direct Response Sales Revenue; in 2016 onwards, 10% of Net Retail Sales and
10% of 60% of Direct Response Sales Revenue. The Annual Minimum Guaranteed Royalty is $120,000 in 2014, $235,000 in 2015, $320,000 in 2016, $345,000 in 2017 and in 2018 onwards, if the Agreement remains in force, will be 75% of the previous
Year's Royalty Calculation or the previous Year's Annual Minimum Guaranteed Royalty plus 10%, whichever is greater.
The agreement was terminated on Dec 31, 2017. On January 17, 2019 Everlast filed a civil lawsuit against the Company.
In that lawsuit, Everlast seeks payment under the License Agreement for $425,555 in unpaid royalties and interest on the unpaid royalties. The Company has accrued the unpaid royalties
as of November 30, 2018
.
Contingencies
The Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. The
Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. There is significant judgment required in both the probability determination and as to whether an exposure can be reasonably
estimated. If any legal matter, that may arise, were resolved against the Company in a reporting period for amounts in excess of management’s expectations, the Company’s would reflect any potential claim in the consolidated financial
statements for that reporting period.
NOTE 11. INCOME TAXES
Deferred tax assets consist of
:
|
|
As of
November 30,
2018
|
|
|
As of
November 30,
2017
|
|
Deferred tax assets:
|
|
|
|
|
|
|
Net operating tax carryforwards
|
|
$
|
1
3
,
622
,
442
|
|
|
$
|
8,915,112
|
|
Tax Rate
|
|
|
21
|
%
|
|
|
35
|
%
|
Gross deferred tax assets
|
|
|
2,860,713
|
|
|
|
3,120,289
|
|
Valuation allowance
|
|
|
(
2,860,713
|
)
|
|
|
(3,120,289
|
)
|
Net deferred tax assets
|
|
$
|
0
|
|
|
$
|
0
|
|
As of November 30, 2018, the Company has a net operating loss carryforward of approximately $
14
million. Net operating loss carryforwards expires twenty years from the date the loss was incurred.
Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that
deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company has recorded a valuation allowance.
Due to the enactment of the Tax Reform Act of 2018, the corporate tax rate for those tax years beginning with 2018
was reduced to 21%.
NOTE 12. SUBSEQUENT EVENTS
On March 11, 2019, each convertible n
ote including the 2018 Convertible Note disclosed in Note 9
were amended to extend
the maturity dates to May 31, 2020.